Investors & Media

What’s new.

Press releases

Press releases.

October 10th 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

October 3rd 2024

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

September 24th 2024

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

September 25th 2024

Canaccord Genuity - Upcoming FDA ODAC meeting puts mounting pressure on Keytruda; Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

September 19th 2024

Capital One - Head and Neck Expert Call – Key Takeaways; Reiterate OW; US$8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 16th 2024

Canaccord Genuity - ESMO update: HNSCC update an incremental positive; Rated Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

more